1-3 of 3 results for subject:Patients
Librarians' tools
- Search time
- 0.152 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Patients
- We searched for
- subject_t:Patients OR subject_t:"Sick people" OR subject_ses:92375
Type
House
Session
Year
Department
Member
Primary member
More
Amess, David (3)
Answering member
Byrne, Liam (3)
More
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health how many serious spinal cord injuries have occurred in each of the last five years.
To ask the Secretary of State for Health how many serious spinal cord injuries have occurred in each of the last five years.
Asked by
David Amess
(Conservative)
Answered by
Liam Byrne
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
29 November 2005
For answer on
1 December 2005
Answered on
14 December 2005
The information requested is shown in the table.
| Count of finished consultant episodes where primary diagnosis is spinal cord injury in national health service hospitals England 1999–2000 to 2003–04 | |
|---|---|
| Finished consultant episodes | |
| 1999–2000 | 698 |
| 2000–01 | 679 |
| 2001–02 | 675 |
| 2002–03 | 825 |
| 2003–04 | 962 |
| Source: Hospital Episode Statistics, Health and Social Care Information Centre |
Subjects
Diagnosis; Patients; Spinal injuries
Date
14 December 2005
Reference
440 c2173W; 34289
House
House of Commons
(5) how many patients are waiting to commence anti-tumour necrosis factor therapy in England.
(5) how many patients are waiting to commence anti-tumour necrosis factor therapy in England.
Asked by
David Amess
(Conservative)
Answered by
Liam Byrne
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
2 November 2005
For answer on
7 November 2005
Answered on
22 November 2005
Anti-tumour necrosis therapy is already commissioned at local level under arrangements that should cover the cost of patient attendances at outpatient clinics as well as any anti-tumour necrosis factor drugs (anti-TNF drugs). From 2006–07, payment by results will apply a national tariff to rheumatology out-patient clinics. The tariff will set the price for out-patient attendances and will exclude the additional cost of anti-TNF drugs, for which funding will continue to be negotiated locally. These arrangements are already operating in 2005–06 for national health service foundation trusts and other early implementers of payment by results.The cost of prescriptions dispensed in the community for the three anti-TNF drugs is shown in the table.
However, the main use for these drugs was in hospitals. An estimate for 2004 costs for anti-TNF drugs dispensed in hospitals, based on a large sample of hospitals, is £71,658,000.Health bodies are obliged to fund, from general allocations, anti-TNF treatment for those with severe rheumatoid arthritis who meet the clinical guidelines set by the National Institute for Health and Clinical Excellence.The Department does not hold information on the number of people who have received anti-TNF treatments.We do not collect information on waiting lists for specific treatments.
| Cost of prescriptions dispensed for anti-TNF drugs, 2000–04 | |
|---|---|
| Cost (£) | |
| 2000 | 12,000 |
| 2001 | 198,000 |
| 2002 | 327,000 |
| 2003 | 833,000 |
| 2004 | 2,312,000 |
Subjects
Medical treatments; Patients; Waiting lists; Arthritis
Date
22 November 2005
Reference
25553; 439 c1799-800W;439 c1801-2W
House
House of Commons
(4) how many patients have received anti-tumour necrosis factor therapy in England in each of the last five years;
(4) how many patients have received anti-tumour necrosis factor therapy in England in each of the last five years;
Asked by
David Amess
(Conservative)
Answered by
Liam Byrne
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
2 November 2005
For answer on
7 November 2005
Answered on
22 November 2005
Anti-tumour necrosis therapy is already commissioned at local level under arrangements that should cover the cost of patient attendances at outpatient clinics as well as any anti-tumour necrosis factor drugs (anti-TNF drugs). From 2006–07, payment by results will apply a national tariff to rheumatology out-patient clinics. The tariff will set the price for out-patient attendances and will exclude the additional cost of anti-TNF drugs, for which funding will continue to be negotiated locally. These arrangements are already operating in 2005–06 for national health service foundation trusts and other early implementers of payment by results.The cost of prescriptions dispensed in the community for the three anti-TNF drugs is shown in the table.
However, the main use for these drugs was in hospitals. An estimate for 2004 costs for anti-TNF drugs dispensed in hospitals, based on a large sample of hospitals, is £71,658,000.Health bodies are obliged to fund, from general allocations, anti-TNF treatment for those with severe rheumatoid arthritis who meet the clinical guidelines set by the National Institute for Health and Clinical Excellence.The Department does not hold information on the number of people who have received anti-TNF treatments.We do not collect information on waiting lists for specific treatments.
| Cost of prescriptions dispensed for anti-TNF drugs, 2000–04 | |
|---|---|
| Cost (£) | |
| 2000 | 12,000 |
| 2001 | 198,000 |
| 2002 | 327,000 |
| 2003 | 833,000 |
| 2004 | 2,312,000 |
Subjects
Medical treatments; Patients; Arthritis
Date
22 November 2005
Reference
25552; 439 c1799-800W;439 c1801-2W
House
House of Commons